RA Capital Management L.P. increased its position in GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,686,689 shares of the company's stock after acquiring an additional 85,000 shares during the quarter. RA Capital Management L.P. owned about 12.85% of GH Research worth $44,734,000 at the end of the most recent quarter.
Separately, Lynx1 Capital Management LP boosted its position in shares of GH Research by 19.8% in the second quarter. Lynx1 Capital Management LP now owns 3,966,726 shares of the company's stock valued at $46,252,000 after acquiring an additional 656,163 shares during the period. 56.90% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages recently issued reports on GHRS. Canaccord Genuity Group dropped their target price on shares of GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a research report on Monday, November 18th. JMP Securities reaffirmed a "market outperform" rating and set a $39.00 price objective on shares of GH Research in a research report on Wednesday, September 4th. Finally, HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of GH Research in a research report on Wednesday, November 20th.
Get Our Latest Research Report on GH Research
GH Research Trading Down 1.0 %
GHRS stock traded down $0.08 during midday trading on Thursday, hitting $7.92. The stock had a trading volume of 11,293 shares, compared to its average volume of 78,401. GH Research PLC has a 52 week low of $5.05 and a 52 week high of $14.99. The stock has a 50-day simple moving average of $8.11 and a 200 day simple moving average of $10.09. The firm has a market capitalization of $412.08 million, a price-to-earnings ratio of -10.13 and a beta of 0.78.
GH Research (NASDAQ:GHRS - Get Free Report) last posted its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. On average, equities analysts forecast that GH Research PLC will post -0.79 EPS for the current year.
GH Research Profile
(
Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Featured Stories
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
